Literature DB >> 7852554

Risk factors for acquiring ampicillin-resistant enterococci and clinical outcomes at a Canadian tertiary-care hospital.

A E McCarthy1, G Victor, K Ramotar, B Toye.   

Abstract

The number of ampicillin-resistant enterococci (ARE) was noted to be increased at our teaching hospital. To determine the risk factors for acquiring this organism and to compare clinical outcomes, over a 5-month period 38 patients infected or colonized with ARE were compared with 76 patients, infected or colonized with ampicillin-susceptible enterococci (ASE). Risk factors included nosocomial acquisition, duration of hospitalization, admission to a medical service, prior antimicrobial therapy, and combination therapy for at least 7 days. The mortality rate of patients infected or colonized with ARE was higher than that of patients infected or colonized with ASE (34 versus 14%; P = 0.03), but most deaths did not appear to be related to enterococcal infection. Over a 2-year period, 16 patients with ARE bacteremia were also compared with 23 patients with ASE bacteremia. The risk factors associated with ARE bacteremia also included nosocomial acquisition, duration of hospitalization, and prior antimicrobial therapy. The mortality of patients with ARE bacteremia was also higher than that of patients with ASE bacteremia (81 versus 30%; P = 0.003), with most deaths being due to the underlying disease or a complication of it. Typing of ARE isolates by pulsed-field gel electrophoresis showed that two genotypes predominated in our institution. A prolonged hospital stay, exposure to multiple antimicrobial agents, and perhaps nosocomial transmission are important factors in acquiring ARE. The presence of ARE may also be a marker for poor outcome.

Entities:  

Mesh:

Year:  1994        PMID: 7852554      PMCID: PMC264140          DOI: 10.1128/jcm.32.11.2671-2676.1994

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  32 in total

1.  Nosocomial infection by gentamicin-resistant Streptococcus faecalis. An epidemiologic study.

Authors:  M J Zervos; C A Kauffman; P M Therasse; A G Bergman; T S Mikesell; D R Schaberg
Journal:  Ann Intern Med       Date:  1987-05       Impact factor: 25.391

2.  Enterococcal bacteremia: analysis of 75 episodes.

Authors:  R M Gullberg; S R Homann; J P Phair
Journal:  Rev Infect Dis       Date:  1989 Jan-Feb

3.  Plasmid-mediated resistance to vancomycin and teicoplanin in Enterococcus faecium.

Authors:  R Leclercq; E Derlot; J Duval; P Courvalin
Journal:  N Engl J Med       Date:  1988-07-21       Impact factor: 91.245

4.  Susceptibility of group D streptococcus (enterococcus) to 21 antibiotics in vitro, with special reference to species differences.

Authors:  P Toala; A McDonald; C Wilcox; M Finland
Journal:  Am J Med Sci       Date:  1969-12       Impact factor: 2.378

5.  Risk factors for acquisition of gentamicin-resistant enterococci. A multivariate analysis.

Authors:  P Axelrod; G H Talbot
Journal:  Arch Intern Med       Date:  1989-06

6.  Nosocomial enterococcal infections: association with use of third-generation cephalosporin antibiotics.

Authors:  C R Magnussen; J Cave
Journal:  Am J Infect Control       Date:  1988-12       Impact factor: 2.918

7.  Ampicillin-resistant enterococcal species in an acute-care hospital.

Authors:  S E Oster; V A Chirurgi; A A Goldberg; S Aiken; R E McCabe
Journal:  Antimicrob Agents Chemother       Date:  1990-09       Impact factor: 5.191

Review 8.  Enterococcal bacteremia: clinical features, the risk of endocarditis, and management.

Authors:  D G Maki; W A Agger
Journal:  Medicine (Baltimore)       Date:  1988-07       Impact factor: 1.889

9.  Enterococci highly resistant to penicillin and ampicillin: an emerging clinical problem?

Authors:  F L Sapico; H N Canawati; V J Ginunas; D S Gilmore; J Z Montgomerie; W J Tuddenham; R R Facklam
Journal:  J Clin Microbiol       Date:  1989-09       Impact factor: 5.948

10.  Enterococcal infections in patients treated with moxalactam.

Authors:  R C Moellering
Journal:  Rev Infect Dis       Date:  1982 Nov-Dec
View more
  7 in total

1.  In vitro activities of 15 antimicrobial agents against clinical isolates of South African enterococci.

Authors:  M C Struwig; P L Botha; L J Chalkley
Journal:  Antimicrob Agents Chemother       Date:  1998-10       Impact factor: 5.191

Review 2.  Emerging resistance to antimicrobial agents in gram-positive bacteria. Enterococci, staphylococci and nonpneumococcal streptococci.

Authors:  M G Cormican; R N Jones
Journal:  Drugs       Date:  1996       Impact factor: 9.546

3.  Enterococcal bacteremia in a tertiary care centre in Winnipeg.

Authors:  T A Madani; A Kabani; P Orr; L Nicolle
Journal:  Can J Infect Dis       Date:  1999-01

4.  vanE gene cluster of vancomycin-resistant Enterococcus faecalis BM4405.

Authors:  Lorena Abadía Patiño; Patrice Courvalin; Bruno Perichon
Journal:  J Bacteriol       Date:  2002-12       Impact factor: 3.490

5.  Near absence of vancomycin-resistant enterococci but high carriage rates of quinolone-resistant ampicillin-resistant enterococci among hospitalized patients and nonhospitalized individuals in Sweden.

Authors:  E Torell; O Cars; B Olsson-Liljequist; B M Hoffman; J Lindbäck; L G Burman
Journal:  J Clin Microbiol       Date:  1999-11       Impact factor: 5.948

6.  Clinical and epidemiological significance of enterococci intrinsically resistant to vancomycin (possessing the vanC genotype)

Authors:  B Toye; J Shymanski; M Bobrowska; W Woods; K Ramotar
Journal:  J Clin Microbiol       Date:  1997-12       Impact factor: 5.948

7.  Enterococcal bacteraemia: predictive and prognostic risk factors for ampicillin resistance.

Authors:  T Matsumura; M Nagao; S Nakano; M Yamamoto; Y Matsumura; S Ichiyama
Journal:  Epidemiol Infect       Date:  2018-08-31       Impact factor: 4.434

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.